Addario Lung Cancer Medical Institute (ALCMI)
@alcmi.bsky.social
The Addario Lung Cancer Medical Institute (ALCMI) is a non-profit international consortium comprised of over 25 of the world's premier oncology research institutions. We fund and support investigator-led lung cancer clinical trials.
Loma Linda University Cancer Center’s Hamid Mirshahidi, MD, is bringing attention to the fact that lung cancer is rising in younger adults, including people who have never smoked, and our risk models and screening strategies are lagging behind. #lungcancer
Lung cancer is showing up in younger adults and smoking isn’t the only cause | News
Young people may overlook warning signs because they think they are not at risk.
news.llu.edu
November 28, 2025 at 3:01 PM
Loma Linda University Cancer Center’s Hamid Mirshahidi, MD, is bringing attention to the fact that lung cancer is rising in younger adults, including people who have never smoked, and our risk models and screening strategies are lagging behind. #lungcancer
To every patient who has enrolled in an ALCMI clinical trial—who has said yes to advancing science even as they face their own uncertain journey—we are profoundly grateful. #lungcancer #thankyou
November 27, 2025 at 3:03 PM
To every patient who has enrolled in an ALCMI clinical trial—who has said yes to advancing science even as they face their own uncertain journey—we are profoundly grateful. #lungcancer #thankyou
Congratulations to our friends at Amgen! The FDA has granted full approval to the company's IMDELLTRA (tarlatamab-dlle), the first therapy to demonstrate a Phase 3 overall survival benefit over chemotherapy in relapsed extensive stage small cell lung cancer (ES-SCLC). #lungcancer
FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER| Amgen
Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy
www.amgen.com
November 26, 2025 at 3:02 PM
Congratulations to our friends at Amgen! The FDA has granted full approval to the company's IMDELLTRA (tarlatamab-dlle), the first therapy to demonstrate a Phase 3 overall survival benefit over chemotherapy in relapsed extensive stage small cell lung cancer (ES-SCLC). #lungcancer
Sevabertinib (Hyrnuo) has just received FDA accelerated approval as a targeted option for HER2-mutant NSCLC, backed by SOHO-01 data showing a 71% response rate in patients without prior HER2-directed therapy. #lungcancer
www.medpagetoday.com/hematologyon...
www.medpagetoday.com/hematologyon...
New FDA-Approved Option for HER2-Mutated Lung Cancer
Sevabertinib produced a 71% response rate in patients without prior HER2-targeted therapy
www.medpagetoday.com
November 25, 2025 at 3:02 PM
Sevabertinib (Hyrnuo) has just received FDA accelerated approval as a targeted option for HER2-mutant NSCLC, backed by SOHO-01 data showing a 71% response rate in patients without prior HER2-directed therapy. #lungcancer
www.medpagetoday.com/hematologyon...
www.medpagetoday.com/hematologyon...
RRAS and RRAS2 mutations have now been defined as recurrent, oncogenic, and potentially actionable drivers in NSCLC by investigators at Memorial Sloan Kettering Cancer Center. #lungcancer
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236
Introduction RRAS and RRAS2 encode a subfamily of RAS-like small GTPases that share considerable structural and functional similarities with KRAS , HRAS , and NRAS. Whether homologous RRAS / RRAS2…
www.biorxiv.org
November 24, 2025 at 3:02 PM
RRAS and RRAS2 mutations have now been defined as recurrent, oncogenic, and potentially actionable drivers in NSCLC by investigators at Memorial Sloan Kettering Cancer Center. #lungcancer
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Researchers at Yale School of Medicine, led by Thazin Nwe Aung, PhD, have developed a "Google Maps–style" spatial multiomics approach to lung cancer, as published in Nature Genetics. #lungcancer
www.oncologynewscentral.com/nsclc/chemot...
www.oncologynewscentral.com/nsclc/chemot...
Chemotherapy-Free Combo Prolongs Survival in EGFR-Mutated Non-Small Cell Lung Cancer
These participants had EGFR exon 19 deletion or L858R substitution mutations and locally advanced or metastatic disease.
www.oncologynewscentral.com
November 23, 2025 at 3:01 PM
Researchers at Yale School of Medicine, led by Thazin Nwe Aung, PhD, have developed a "Google Maps–style" spatial multiomics approach to lung cancer, as published in Nature Genetics. #lungcancer
www.oncologynewscentral.com/nsclc/chemot...
www.oncologynewscentral.com/nsclc/chemot...
Christine Hann, MD, PhD, of Johns Hopkins Medicine, highlighted significant immunotherapy advancements and persistent challenges in small cell lung cancer at the 20th Annual New York Lung Cancers Symposium. #lungcancer
www.onclive.com/view/immunot...
www.onclive.com/view/immunot...
Immunotherapy Advances in SCLC Highlight Promise, Limitations, and Biomarker Needs | OncLive
Christine Hann, MD, PhD, discusses how recently presented SCLC data inform treatment decision-making across the LS-SCLC and ES-SCLC settings.
www.onclive.com
November 22, 2025 at 3:00 PM
Christine Hann, MD, PhD, of Johns Hopkins Medicine, highlighted significant immunotherapy advancements and persistent challenges in small cell lung cancer at the 20th Annual New York Lung Cancers Symposium. #lungcancer
www.onclive.com/view/immunot...
www.onclive.com/view/immunot...
DC vaccination combined with atezolizumab has shown encouraging long-term survival in extensive-stage small cell lung cancer. #lungcancer
www.cancernetwork.com/view/atezoli...
www.cancernetwork.com/view/atezoli...
Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC | CancerNetwork
Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.
www.cancernetwork.com
November 21, 2025 at 3:01 PM
DC vaccination combined with atezolizumab has shown encouraging long-term survival in extensive-stage small cell lung cancer. #lungcancer
www.cancernetwork.com/view/atezoli...
www.cancernetwork.com/view/atezoli...
A multi-institutional team has defined the maximum tolerated dose of olaparib combined with thoracic radiotherapy in extensive-stage small cell lung cancer, marking the first clinical demonstration that this radiosensitizing strategy can be delivered safely. #lungcancer
Phase I Dose-Escalation Trial Combining Olaparib and Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
AbstractPurpose:. Patients with extensive-stage small cell lung cancer are commonly treated with induction systemic therapy and consolidative thoracic radiotherapy (TRT). PARP inhibitors have…
aacrjournals.org
November 20, 2025 at 3:03 PM
A multi-institutional team has defined the maximum tolerated dose of olaparib combined with thoracic radiotherapy in extensive-stage small cell lung cancer, marking the first clinical demonstration that this radiosensitizing strategy can be delivered safely. #lungcancer
Congratulations to our friends at Boehringer Ingelheim! The FDA has awarded the company a Commissioner’s National Priority Voucher (CNPV) for zongertinib. #lungcancer
Boehringer awarded FDA Commissioner’s National Priority Voucher for zongertinib in patients with HER2-mutant NSCLC
This recognition underscores the potential of zongertinib to meet critical patient needs for this rare and aggressive cancer.
www.boehringer-ingelheim.com
November 19, 2025 at 3:05 PM
Congratulations to our friends at Boehringer Ingelheim! The FDA has awarded the company a Commissioner’s National Priority Voucher (CNPV) for zongertinib. #lungcancer
Synthekine has reported encouraging early results from its Phase Ia/Ib study of STK-012, an interleukin-2 receptor α/β–biased partial agonist, in first-line PD-L1–negative non-squamous non-small cell lung cancer. #lungcancer
www.clinicaltrialsarena.com/news/synthek...
www.clinicaltrialsarena.com/news/synthek...
Synthekine reports initial STK-012 data in lung cancer trial
Synthekine has reported positive initial data from a Phase Ia/Ib trial evaluating STK-012 in first-line, programmed death-ligand 1 (PD-L1)-negative nonsquamous non-small cell lung cancer (NSCLC).
www.clinicaltrialsarena.com
November 18, 2025 at 3:03 PM
Synthekine has reported encouraging early results from its Phase Ia/Ib study of STK-012, an interleukin-2 receptor α/β–biased partial agonist, in first-line PD-L1–negative non-squamous non-small cell lung cancer. #lungcancer
www.clinicaltrialsarena.com/news/synthek...
www.clinicaltrialsarena.com/news/synthek...
The American Lung Association’s 2025 State of Lung Cancer report shows U.S. five-year survival has risen to 29.7%, yet only 18.2% of eligible adults were screened in 2022, and significant racial disparities persist. #lungcancer
www.lung.org/research/sta...
www.lung.org/research/sta...
State of Lung Cancer
Examining lung cancer incidence, survival, stage at diagnosis, surgical treatment, lack of treatment, and screening, this report finds states must do more to protect their residents from lung cancer.
www.lung.org
November 17, 2025 at 3:04 PM
The American Lung Association’s 2025 State of Lung Cancer report shows U.S. five-year survival has risen to 29.7%, yet only 18.2% of eligible adults were screened in 2022, and significant racial disparities persist. #lungcancer
www.lung.org/research/sta...
www.lung.org/research/sta...
Radiomics-guided biopsies are an exciting new area that helps define lung cancer heterogeneity. #lungcancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Targeting tumoral heterogeneity in lung cancer: a novel, CT-texture-guided targeted biopsy approach with exome sequencing - npj Precision Oncology
npj Precision Oncology - Targeting tumoral heterogeneity in lung cancer: a novel, CT-texture-guided targeted biopsy approach with exome sequencing
www.nature.com
November 16, 2025 at 3:02 PM
Radiomics-guided biopsies are an exciting new area that helps define lung cancer heterogeneity. #lungcancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Artificial intelligence is proving to be a powerful tool in detecting lung cancer and determining who gets screened. #lungcancer
www.diagnosticimaging.com/view/prospec...
www.diagnosticimaging.com/view/prospec...
Prospective Study Shows Capability of CXR AI to Detect Early-Stage Lung Cancer in Young Patients and Never Smokers | Diagnostic Imaging
In a recent interview, Hari Kishan Gonuguntla, M.D., discussed AI-powered evaluation of chest X-rays with the Lung Nodule Malignancy Score software and key findings from multinational prospective…
www.diagnosticimaging.com
November 15, 2025 at 3:02 PM
Artificial intelligence is proving to be a powerful tool in detecting lung cancer and determining who gets screened. #lungcancer
www.diagnosticimaging.com/view/prospec...
www.diagnosticimaging.com/view/prospec...
In a study published in Cell, Dr. Charles Swanton and the TRACERx Consortium applied personalized liquid biopsy techniques to nearly 3,000 plasma samples from 431 NSCLC patients, revealing that ctDNA levels carry powerful prognostic value both before and after surgery. #lungcancer
Ultrasensitive Liquid Biopsy Approach Improves Lung Cancer Patient Stratification
Circulating tumor DNA levels before and after surgery provided insights into disease trajectories and clinical outcomes for hundreds of non-small cell lung cancer patients.
www.genomeweb.com
November 14, 2025 at 3:03 PM
In a study published in Cell, Dr. Charles Swanton and the TRACERx Consortium applied personalized liquid biopsy techniques to nearly 3,000 plasma samples from 431 NSCLC patients, revealing that ctDNA levels carry powerful prognostic value both before and after surgery. #lungcancer
Early data from Memorial Sloan Kettering Cancer Center researchers showed promising efficacy for STK‑012 plus pembrolizumab and chemotherapy in PD‑L1–negative nonsquamous NSCLC. #lungcancer
www.onclive.com/view/frontli...
www.onclive.com/view/frontli...
Frontline STK-012 Plus Pembrolizumab and Chemo Shows Early Promise in PD-L1–Negative NSCLC | OncLive
STK-012 plus pembrolizumab and chemotherapy showed early efficacy and manageable safety in PD-L1–negative NSCLC.
www.onclive.com
November 13, 2025 at 3:04 PM
Early data from Memorial Sloan Kettering Cancer Center researchers showed promising efficacy for STK‑012 plus pembrolizumab and chemotherapy in PD‑L1–negative nonsquamous NSCLC. #lungcancer
www.onclive.com/view/frontli...
www.onclive.com/view/frontli...
In a new Mayo Clinic article, Dr. Velcheti outlines how advances in precision diagnostics, immunotherapy, and multidisciplinary collaboration are transforming lung cancer outcomes. #lungcancer
www.mayoclinic.org/medical-prof...
www.mayoclinic.org/medical-prof...
Innovations for improved lung cancer outcomes - Mayo Clinic
Nov. 04, 2025
www.mayoclinic.org
November 12, 2025 at 3:03 PM
In a new Mayo Clinic article, Dr. Velcheti outlines how advances in precision diagnostics, immunotherapy, and multidisciplinary collaboration are transforming lung cancer outcomes. #lungcancer
www.mayoclinic.org/medical-prof...
www.mayoclinic.org/medical-prof...
The FDA has cleared the IND application for ILKN421H (STI-7349), a novel mRNA-based IL-2 variant from iLeukon Therapeutics, to advance into phase 2 studies in advanced non–small cell lung cancer. #lungcancer
www.cancernetwork.com/view/fda-cle...
www.cancernetwork.com/view/fda-cle...
FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC | CancerNetwork
ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.
www.cancernetwork.com
November 11, 2025 at 3:03 PM
The FDA has cleared the IND application for ILKN421H (STI-7349), a novel mRNA-based IL-2 variant from iLeukon Therapeutics, to advance into phase 2 studies in advanced non–small cell lung cancer. #lungcancer
www.cancernetwork.com/view/fda-cle...
www.cancernetwork.com/view/fda-cle...
Wow! The American Lung Association Research Institute has committed $22 million to lung disease and lung cancer research, an unprecedented investment during a year of federal funding instability. #lungcancer
www.lung.org/media/press-...
www.lung.org/media/press-...
Lung Association Steps Up with $22 Million in Research Funding as Federal Support for Science Wavers
Today, the American Lung Association Research Institute announced it has invested $22 million in new research grants, clinical research and strategic partnerships to advance the understanding,…
www.lung.org
November 10, 2025 at 3:03 PM
Wow! The American Lung Association Research Institute has committed $22 million to lung disease and lung cancer research, an unprecedented investment during a year of federal funding instability. #lungcancer
www.lung.org/media/press-...
www.lung.org/media/press-...
A shift in the first-line management of EGFR-mutated non–small cell lung cancer (NSCLC) is upon us, according to Anastasios Dimou, M.D., and Aaron Mansfield, M.D., in their editorial published in NEJM Group. #lungcancer
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
EGFR-Mutated Lung Cancer — Letting the Butterfly Out of the Cocoon | NEJM
Somatic mutations in EGFR (epidermal growth factor receptor) account for approximately one third of lung cancer cases worldwide.1 A point mutation in exon 21 (L858R) or a short deletion in exon 19 ...
www.nejm.org
November 9, 2025 at 3:01 PM
A shift in the first-line management of EGFR-mutated non–small cell lung cancer (NSCLC) is upon us, according to Anastasios Dimou, M.D., and Aaron Mansfield, M.D., in their editorial published in NEJM Group. #lungcancer
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
New study alert! The DESTINY-Lung06 phase 3 trial has officially launched, marking the first global study to evaluate ENHERTU (trastuzumab deruxtecan) plus pembrolizumab as a first-line treatment for HER2 overexpressing metastatic non-squamous NSCLC. #lungcancer
finance.yahoo.com/news/destiny...
finance.yahoo.com/news/destiny...
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J., October 31, 2025--DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic NSCLC
finance.yahoo.com
November 8, 2025 at 3:01 PM
New study alert! The DESTINY-Lung06 phase 3 trial has officially launched, marking the first global study to evaluate ENHERTU (trastuzumab deruxtecan) plus pembrolizumab as a first-line treatment for HER2 overexpressing metastatic non-squamous NSCLC. #lungcancer
finance.yahoo.com/news/destiny...
finance.yahoo.com/news/destiny...
If you have a clinical trial idea, we're here to help you get it off the ground. #lungcancer
alcmi.org/researcher-p...
alcmi.org/researcher-p...
Partner with ALCMI to Drive Lung Cancer Research Forward
Explore ALCMI’s Researcher Portal for tools, funding, and collaboration opportunities that empower investigator-initiated lung cancer clinical trials and breakthrough discoveries.
alcmi.org
November 7, 2025 at 3:03 PM
If you have a clinical trial idea, we're here to help you get it off the ground. #lungcancer
alcmi.org/researcher-p...
alcmi.org/researcher-p...
Frozen section pathology improves intraoperative decision-making in early-stage lung cancer surgery, according to new research from Mayo Clinic thoracic surgeons and pulmonary pathologists. #lungcancer
www.mayoclinic.org/medical-prof...
www.mayoclinic.org/medical-prof...
Frozen section pathology enhances intraoperative decision-making in early-stage lung cancer surgery - Mayo Clinic
Nov. 01, 2025
www.mayoclinic.org
November 6, 2025 at 3:04 PM
Frozen section pathology improves intraoperative decision-making in early-stage lung cancer surgery, according to new research from Mayo Clinic thoracic surgeons and pulmonary pathologists. #lungcancer
www.mayoclinic.org/medical-prof...
www.mayoclinic.org/medical-prof...
Pafolacianine has advanced the surgical resection of early-stage non-small cell lung cancer, enabling surgeons to detect and remove lesions previously missed by conventional techniques. #lungcancer
www.mayoclinic.org/medical-prof...
www.mayoclinic.org/medical-prof...
New drug helps Mayo Clinic surgeons detect smaller lesions with greater accuracy during lung cancer surgery - Mayo Clinic
Oct. 21, 2025
www.mayoclinic.org
November 4, 2025 at 3:03 PM
Pafolacianine has advanced the surgical resection of early-stage non-small cell lung cancer, enabling surgeons to detect and remove lesions previously missed by conventional techniques. #lungcancer
www.mayoclinic.org/medical-prof...
www.mayoclinic.org/medical-prof...
Researchers at Cedars-Sinai Medical Center have published one of the most comprehensive national analyses to date on surgical timing for early-stage non-small cell lung cancer, using data from 219,723 patients in the National Cancer Database. #lungcancer
pubmed.ncbi.nlm.nih.gov/40950869/
pubmed.ncbi.nlm.nih.gov/40950869/
Wait times between lung cancer diagnosis and surgery: national trends, disparities, and impact on long-term survival - PubMed
Wait times exceeding 4 weeks between lung cancer diagnosis and surgery for stage I and II NSCLC are increasingly common, particularly among non-Hispanic Black patients, and are associated with worse…
pubmed.ncbi.nlm.nih.gov
November 3, 2025 at 3:04 PM
Researchers at Cedars-Sinai Medical Center have published one of the most comprehensive national analyses to date on surgical timing for early-stage non-small cell lung cancer, using data from 219,723 patients in the National Cancer Database. #lungcancer
pubmed.ncbi.nlm.nih.gov/40950869/
pubmed.ncbi.nlm.nih.gov/40950869/